Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Asset Management Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Asset Management Ventures

Asset Management Ventures

Operating

Asset Management Ventures: A US-based venture capital firm investing in early-stage IT and health science tech.

Location
Palo Alto, CA, US
Founded
1965
Firm
Compare
Portfolio
Employees
Website

Investments

basys.ai
basys.ai

Total Raised

$2.4M

Rounds

1

Pre-Seed$2.4MJuly 2023
Autonomize
Autonomize

Total Raised

$4M

Rounds

1

Seed$4MApril 2023
SubjectWell
SubjectWell

Total Raised

$46.8M

Rounds

6

Series B$35MOctober 2022
Carta Healthcare
Carta Healthcare

Total Raised

$42.3M

Rounds

6

Series B$20MJuly 2022
Series A$17.3MApril 2021
Series AMarch 2019
Secure AI Labs
Secure AI Labs

Total Raised

$8.1M

Rounds

2

Seed$4.7MJuly 2022
Pre-Seed$3.4MJanuary 2020
Outcomes4Me
Outcomes4Me

Total Raised

$16.7M

Rounds

2

Series A$12MApril 2021
Seed$4.7MNovember 2020
Lark
Lark

Total Raised

$195.7M

Rounds

9

Series C$55MOctober 2020
Decent
Decent

Total Raised

$18M

Rounds

2

Series A$10MSeptember 2020
Reify Health
Reify Health

Total Raised

$479.6M

Rounds

7

Series B$30MAugust 2020
Unnatural Products
Unnatural Products

Total Raised

$38M

Rounds

4

Seed$6MSeptember 2019
Arterys
Arterys
Acquired

Total Raised

$71.7M

Rounds

9

DebtJuly 2019
UniKey Technologies
UniKey Technologies
Debt

Total Raised

$17.9M

Rounds

9

DebtJuly 2019
Debt$5MJune 2017
Welkin Health
Welkin Health

Total Raised

$29M

Rounds

6

Series B$17.5MMay 2019
Mightier
Mightier
Series B

Total Raised

$29.3M

Rounds

8

Series A$6.6MMay 2019
InCarda Therapeutics
InCarda Therapeutics
Series A

Total Raised

$86.4M

Rounds

9

Series B$42MNovember 2018
Properly
Properly

Total Raised

$8.5M

Rounds

4

Series A$8.5MOctober 2018
3T Biosciences
3T Biosciences

Total Raised

$52M

Rounds

3

Seed$12MOctober 2017
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series A$7MAugust 2017
Indi Molecular
Indi Molecular

Total Raised

$13.3M

Rounds

3

Series A$11.5MJune 2017
Amygdala Neurosciences
Amygdala Neurosciences

Total Raised

$8.9M

Rounds

5

SeedMay 2017